Brolucizumab: all 35 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.CompletedNCT04774926Phase 4Results posted
• Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular DegenerationCompletedNCT04679935Phase 4Results posted
• An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) StudyCompletedNCT04597632Phase 3Results posted
• Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic RetinopathyCompletedNCT04278417Phase 3Results posted
• Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular DegenerationCompletedNCT04264819Phase 3Results posted
• A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular DegenerationCompletedNCT04239027Phase 3Results posted
• To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular EdemaCompletedNCT04058067Phase 3Results posted
• Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular DegenerationCompletedNCT04047472Phase 3Results posted
• Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)CompletedNCT04005352Phase 3Results posted
• Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMDCompletedNCT03954626Phase 3Results posted
• Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular DegenerationCompletedNCT03930641Phase 3Results posted
• Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaCompletedNCT03917472Phase 3Results posted
• Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein OcclusionTerminatedNCT03810313Phase 3Results posted
• Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein OcclusionTerminatedNCT03802630Phase 3Results posted
• Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF InjectionsTerminatedNCT03710564Phase 3Results posted
• A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaCompletedNCT03481660Phase 3Results posted
• Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaCompletedNCT03481634Phase 3Results posted
• Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMDCompletedNCT03386474Phase 3Results posted
• Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular DegenerationCompletedNCT02507388Phase 2Results posted
• Efficacy and Safety of RTH258 Versus Aflibercept - Study 2CompletedNCT02434328Phase 3Results posted
• Efficacy and Safety of RTH258 Versus Aflibercept - Study 1CompletedNCT02307682Phase 3Results posted
• ESBA1008 Microvolume StudyCompletedNCT01849692Phase 2Results posted
• Efficacy and Safety Study of ESBA1008 Versus EYLEA®CompletedNCT01796964Phase 2Results posted
• ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) PatientsCompletedNCT01304693Phase 1/2Results posted
• Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular EdemaCompletedNCT07096713Not applicable
• Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.CompletedNCT05959304Phase 4
• Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&ECompletedNCT05710471Phase 4
• Prospective triAl of Modified Treat-and-extend Regimens With BroLucizumab in pachychOroid NeovasculopathyStatus unknownNCT05672979Phase 3
• Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal VasculopathyCompletedNCT05666804Phase 3
• Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMDActive, not recruitingNCT04932980Not applicable
• Brolucizumab vs. Aflibercept for Retinal Angiomatous ProliferationWithdrawnNCT04698850Phase 4
• Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)WithdrawnNCT04697953Phase 3
• BEOVU in the Treatment of Dystrophy-related Macular Neovascular DegenerationStatus unknownNCT04690062Phase 4
• Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to AfliberceptTerminatedNCT04287348Phase 4
• Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaWithdrawnNCT04079231Phase 3

← Brolucizumab overview